In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

C-Path Proposes NSCLC Initiative for EGFr Drugs and Diagnostics

Executive Summary

In an encouraging sign for drug/diagnostic co-development, the independently funded C-Path Institute is now engaging more than 20 pharma and diagnostics companies with interests in non-small-cell lung cancer treatment using EGF receptor-targeted drugs and diagnostics. This proposed initiative could forge a template for future FDA reviews of drugs and companion diagnostics.
Advertisement

Related Content

New Initiatives to Improve Diagnostic Data Access
New Initiatives to Improve Diagnostic Data Access
A Critical Test for FDA's Critical Path Initiative
AstraZeneca's Iressa Problem
AstraZeneca's Iressa Problem

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002793

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel